Multiple Sclerosis and Smoking

The objectives of this review were to examine the relationship between smoking and MS and to understand the possible molecular mechanisms underlying the association.PubMed was searched for articles related to the study topic published between 2012 and 2020 using the search terms "multiple sclerosis," "smoking," "risk factors," "cigarettes," and "molecular mechanisms."Studies show a significant relationship between smoking and the risk of MS.
Source: The American Journal of Medicine - Category: General Medicine Authors: Tags: Review Source Type: research

Related Links:

Purpose of review This review aims to update the studies involving the treatment of lower urinary tract symptoms (LUTS) in neurogenic patients, published in the last two years. Recent findings Treatment of neurogenic LUTS (NLUTS) patients with β3 adrenoreceptor agonists was investigated in real-life conditions. A randomized controlled trial compared the efficacy of antimuscarinics versus onabotulinum toxin A in neurogenic patients. The use of desmopressin to treat nocturia in multiple sclerosis patients is also reported. The long-term treatment with BontA efficacy, its discontinuation, and possible strategies to ...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: NEUROUROLOGY AND INCONTINENCE: Edited by John Heesakkers and Frank Martens Source Type: research
Authors: Fonti GL, Chimenti MS, Greco E, Boffa L, Conigliaro P, Triggianese P, Perricone R PMID: 32452349 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
Authors: Macaluso F, Guggino G, Ciccia F PMID: 32452343 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
             Basel, 28 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced European Medicines Agency (EMA) approval of a new, shorter two-hour OCREVUS ® (ocrelizumab) infusion time, dosed twice yearly, for relapsing or primary progressive multiple sclerosis (MS). The approval is based on a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP).“The approval of a shorter, two-hour infusion time for OCREVUS in Europe, dosed twice yearly, will further improve the treatment experience for patients while als...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Authors: Zanghì A, Cimino S, Urzì D, Privitera S, Zagari F, Lanza G, Patti F, D'Amico E Abstract INTRODUCTION: Multiple Sclerosis (MS) manifests with a plethora of signs and symptoms affecting brain structures and spinal pathways. The multitude of lesions in MS patients makes difficult to establish the relative role of each of them to lower urinary tract symptoms (LUTS). Generally, the subcortical white-matter lesions result in detrusor overactivity, whilst lesions of the spinal cord result in the combined occurrence of detrusor overactivity and detrusor-sphincter dyssynergia (DSD). It has been estima...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Authors: de Sire A, Mauro A, Priano L, Baudo S, Bigoni M, Solaro C Abstract Multiple sclerosis (MS) is a chronic disease of the central nervous system, characterized by demyelinization and axonal loss resulting, in 66% of cases, in upper limb motor impairment. The effects of constraint-induced movement therapy (CIMT) have recently been investigated in MS patients. The aim of this randomized single-blind pilot study was to assess the effects of CIMT on upper limb activity, specifically smoothness of movement, in patients affected by progressive MS. Patients affected by MS, and reporting reduced use primarily of one ...
Source: Functional Neurology - Category: Neurology Tags: Funct Neurol Source Type: research
Conclusions: Including selected drugs in risk adjustment improved the models’ predictive power. In addition, inclusion of selected drugs may discourage insurers from using formulary and drug benefit design to avoid enrollment of patients taking high-cost drugs, such as for HIV, multiple sclerosis, and rheumatoid arthritis, and improve access for enrollees taking these drugs. Adding RXCs also may improve plan risk measurement for plans with less complete diagnosis reporting.
Source: Medical Care - Category: Health Management Tags: Original Articles Source Type: research
Publication date: Available online 26 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Elizabeth S. Gromisch, Joseph F. Kulas, Hamada Altalib, Robert D. Kerns, Kristin M. Mattocks, Cynthia A. Brandt, Sally Haskell
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Publication date: Available online 26 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Andréa Gomes Moraes, Silvia Gonçalves Ricci Neri, Robert W. Motl, Carlos Bernardo Tauil, Felipe von Glehn Silva, Éber Castro Corrêa, Ana Cristina de David
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Living in highly polluted urban areas is associated with a greater risk of developing multiple sclerosis than living in less polluted areas, a large population-based study suggests.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
More News: Brain | General Medicine | Multiple Sclerosis | Neurology | Smokers | Study